Making smart investment decisions in clinical research

about

Costs of drugs for treatment of rheumatic diseases.

P2860

Q47164070-07D10DDF-0B62-407D-A281-9955099F3DA8

P2860

Making smart investment decisions in clinical research

Item

http://www.wikidata.org/entity/Q36409914

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Making smart investment decisions in clinical research

@ast

Making smart investment decisions in clinical research

@en

type

Item

label

Making smart investment decisions in clinical research

@ast

Making smart investment decisions in clinical research

@en

prefLabel

Making smart investment decisions in clinical research

@ast

Making smart investment decisions in clinical research

@en

P1476

Making smart investment decisions in clinical research

@en

P2093

Aslam Anis

http://www.w3.org/2001/XMLSchema#string

Ciaran S Phibbs

http://www.w3.org/2001/XMLSchema#string

Edward Keystone

http://www.w3.org/2001/XMLSchema#string

James O'Dell

http://www.w3.org/2001/XMLSchema#string

Keri Hannagan

http://www.w3.org/2001/XMLSchema#string

Mary Brophy

http://www.w3.org/2001/XMLSchema#string

P2860

Biologics for rheumatoid arthritis: an overview of Cochrane reviews

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

Effect of combination therapy on joint destruction in rheumatoid arthritis: a network meta-analysis of randomized controlled trials

A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial

Potential biologic agents for treating rheumatoid arthritis.

Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial.

Therapies for active rheumatoid arthritis after methotrexate failure.

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial.

P2888

s13063-015-1123-1

P304

590

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1186/S13063-015-1123-1

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Nick Bansback

P577

2015-12-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

288701627

http://www.w3.org/2001/XMLSchema#string

P6179

1006332189

http://www.w3.org/2001/XMLSchema#string

P698

26712327

http://www.w3.org/2001/XMLSchema#string

P932

4693420

http://www.w3.org/2001/XMLSchema#string

Making smart investment decisions in clinical research

about

P2860

P2860

Making smart investment decisions in clinical research

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P50

P577

P5875

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P50

P577

P5875

P6179

P698

P932